Abstract
Objective:
This study focused on comparing the efficacy of uniportal three-dimensional (3D) video-assisted thoracic surgery (VATS) lobectomy and traditional two-dimensional (2D) VATS lobectomy in patients with non-small cell lung cancer (NSCLC).
Methods:
A retrospective analysis was performed on 84 NSCLC patients who underwent VATS lobectomy. Based on the type of thoracoscope used during surgery, patients were assigned to either the 3D group (n = 42), which received uniportal 3D VATS lobectomy, or the 2D group (n = 42), which underwent traditional 2D VATS lobectomy. Perioperative indicators, postoperative Visual Analog Scale (VAS) scores, pain-related factors [substance P (SP), norepinephrine (NE), and cortisol (COR)], immune function (CD3+, CD4+, and CD8+), lung function [forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), and maximal voluntary ventilation (MVV)] were compared between the two groups.
Results:
The 3D group exhibited lower intraoperative blood loss, postoperative 24-hour drainage volume, drainage tube indwelling time, surgery duration, and hospitalization time compared to the 2D group (P < 0.05). Postoperatively, the 3D group reported lower VAS scores, lower levels of SP, NE, and COR, higher serum levels of CD3+ and CD4+, and higher FVC, FEV1, and MVV values compared to the 2D group (all P < 0.05).
Conclusion:
Uniportal 3D VATS lobectomy demonstrates clear advantages over traditional 2D VATS lobectomy for NSCLC patients by reducing perioperative pain, minimizing immune impairment, and preserving lung function.
Keywords
Get full access to this article
View all access options for this article.